Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Leukemia & Lymphoma Society awards SCOR program grant to Walter and Eliza Hall Institute team

Research into the natural process of cell death, its role in the development of blood cancers and harnessing cell death to improve cancer therapies has seen a Walter and Eliza Hall Institute research team from Melbourne, Australia, awarded a grant of more than $6 million by the US-based Leukemia & Lymphoma Society.

7 Sep 2012

Sorafenib could be effective against multiple myeloma

Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable.

6 Sep 2012

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

Epizyme, Inc., a company leading the creation of a new class of personalized therapeutics for patients with genetically defined cancers, announced today that it has initiated a Phase 1 Study of EPZ-5676. EPZ-5676 is a novel small molecule inhibitor of DOT1L, a histone methyltransferase (HMT) that is critical to the development of a specific type of acute leukemia defined by rearrangement of the MLL gene (MLL-r leukemia).

5 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Weill Cornell Medical College has been awarded three new research grants from the Leukemia & Lymphoma Society totaling $1.8 million. The funds will support critically-needed translational research for blood cancers, accelerating promising discoveries from the laboratory to the patient's bedside.

31 Aug 2012

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has executed a global license and development agreement with the Danish company Genmab A/S for the anti-cancer compound, daratumumab.

30 Aug 2012

NCCN announces new guidelines for patients with pancreatic Cancer

The National Comprehensive Cancer Network (NCCN), with the support of the Pancreatic Cancer Action Network, announces the latest addition to the library of NCCN Guidelines for PatientsTM, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

30 Aug 2012

Life-quality concerns for multiple myeloma survivors

Care of patients with multiple myeloma should not end with the achievement of long-term survival, suggests research indicating many experience poor health-related quality of life in the decade after diagnosis.

22 Aug 2012

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Arteriocyte, a leading clinical stage biotechnology company developing cellular based therapies to treat human diseases, announced today the successful award of another grant by the National Institute of Health for the use of the NANEX platform in Hematopoietic Reconstitution Using Ex Vivo Expanded Umbilical Cord Blood CD34+ Stem Cells.

22 Aug 2012

Mayo Clinic receives approval for construction of new building on Phoenix campus

Mayo Clinic has been granted approval for construction of a 217,200 square-foot building on its Phoenix campus, a major expansion that will create a single-site, integrated Cancer Center. Mayo Clinic Cancer Center is the only National Cancer Institute-designated comprehensive cancer center with a multi-site, national presence, which allows us to serve a broad and diverse group of patients.

21 Aug 2012

Researchers use small molecule compound to generate reversible birth control in male mice

The development of a male contraceptive pill has long proven to be elusive, but findings from a new study may point scientists in the right direction to making oral birth control for men a reality.

17 Aug 2012

Combination of obatoclax and flavopiridol triggers multiple myeloma cell death

Researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory and animal experiments involving a new combination therapy for multiple myeloma, the second most common form of blood cancer.

15 Aug 2012

Possible molecular link between circadian rhythm disturbances and increased inflammatory response

Scientists have known for some time that throwing off the body's circadian rhythm can negatively affect body chemistry. In fact, workers whose sleep-wake cycles are disrupted by night shifts are more susceptible to chronic inflammatory diseases such as diabetes, obesity and cancer.

2 Aug 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas

Senesco Technologies, Inc. reported today that it was informed on July 26th that the U.S. Food and Drug Administration has granted orphan-drug designation for the company's lead drug candidate SNS01-T for treatment of both mantle cell lymphoma and diffuse large B-cell lymphoma.

30 Jul 2012

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published in Blood, a major peer-reviewed scientific journal.

26 Jul 2012

Karyopharm commences two KPT-330 phase 1 studies in cancers

Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced dosing of patients in the first-in-human clinical trials with KPT-330.

25 Jul 2012

EntreMed commences ENMD-2076 Phase 2 study in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.

25 Jul 2012

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Biokine Therapeutics Ltd. announced today that it has received Orphan Drug designation from the US Food and Drug Administration (FDA) for the mobilization of hematopoietic stem cells from bone marrow into peripheral blood for collection and subsequent transplantation in patients with hematological cancers.

24 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Leukemia & Lymphoma Society awards SCOR program grant to Walter and Eliza Hall Institute team

Sorafenib could be effective against multiple myeloma

Epizyme commences EPZ-5676 Phase 1 study for MLL-r leukemia

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

Weill Cornell Medical College receives three new research grants for translational blood cancer study

Genmab, Janssen partner to develop and commercialize daratumumab for multiple myeloma

NCCN announces new guidelines for patients with pancreatic Cancer

Life-quality concerns for multiple myeloma survivors

Arteriocyte receives NIH grant for use of NANEX platform in bone marrow transplant

Mayo Clinic receives approval for construction of new building on Phoenix campus

Researchers use small molecule compound to generate reversible birth control in male mice

Combination of obatoclax and flavopiridol triggers multiple myeloma cell death

Possible molecular link between circadian rhythm disturbances and increased inflammatory response

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Karyopharm commences two KPT-330 phase 1 studies in cancers

EntreMed commences ENMD-2076 Phase 2 study in triple-negative breast cancer

Biokine receives FDA Orphan Drug designation for BKT140 to treat hematological cancers

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in